CCX168 + Midazolam + Celecoxib + Itraconazole + Rifampicin
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Conditions
Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Trial Timeline
Jan 14, 2016 → Jun 10, 2016
NCT ID
NCT06004947About CCX168 + Midazolam + Celecoxib + Itraconazole + Rifampicin
CCX168 + Midazolam + Celecoxib + Itraconazole + Rifampicin is a phase 1 stage product being developed by Amgen for Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis. The current trial status is completed. This product is registered under clinical trial identifier NCT06004947. Target conditions include Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06004947 | Phase 1 | Completed |
Competing Products
5 competing products in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan + Placebo + Rituximab | Novartis | Phase 2 | 52 |
| Rituximab + Azathioprine | Roche | Phase 3 | 77 |
| CCX168 | Amgen | Phase 1 | 32 |
| CCX168 + Placebo | Amgen | Phase 1 | 32 |
| [14C]CCX168 | Amgen | Phase 1 | 32 |